血管舒缓素治疗早期糖尿病肾病的疗效观察  

Efficacy of kallikrein on patients with early diabetic nephropathy

作　　者：张怡 张吉胜 陈其军 范汪洋 应一樱 

机构地区：[1]宁波市鄞州第二医院,浙江宁波315010

出　　处：《浙江医学教育》2013年第5期51-53,56,共4页Zhejiang Medical Education

摘　　要：目的:探讨血管舒缓素治疗早期糖尿病肾病的临床疗效。方法:选择血糖控制平稳的早期糖尿病肾病患者76例,随机分为2组,对照组予常规降糖、降压治疗,治疗组在常规治疗基础上加用血管舒缓素肠溶片,观察治疗后患者24小时尿蛋白定量、肾功能及血液流变学指标。结果:治疗组治疗有效率为81.58%,明显高于对照组的34.21%,差异有统计学意义(P<0.05);治疗后治疗组患者24小时尿蛋白定量较治疗前明显下降(P<0.05),且下降程度明显低于对照组(P<0.05);2组患者治疗后全血比黏度(高、中、低切)及血浆黏度均有明显下降(P<0.05),且治疗后治疗组上述指标明显低于对照组(P<0.05)。结论:血管舒缓素可显著降低患者24小时尿蛋白水平,改善早期糖尿病肾病患者肾小球血液动力学指标。[ Objective] To investigate the clinical efficacy of kallikrein on patients with early diabetic nephropathy. [Method] 76 patients with early diabetic nephropathy were randomly divided into two groups. The control group was treated with conventional antidiabetic and antihypertensive. The treatment group was treated with kallikrein besides the conventional treataent. The serum crealinine, blood urea nitrogen and blood rheology indicators were compared before and after treatment. [ Result] Thempy effective rate in treatment group was 81.58% and it was significantly higher than the control group （34.21% ）. In treatment group, the urinary protein excretion decreased significantly after treated （ P 〈 0.05 ）, and the urine protein levels were significantly lower than those in control group （P 〈 0.05）. The whole blood viscosity （high, medium, low cut） and plasma viscosity were significantly decreased （P 〈 0.05） in two groups, but these parameters in the treatment group were significantly lower （P 〈0.05）. [ Conclusion] The kallikrein in treating early diabetic nephropathy can reduce the urinary protein and improve the glomerular hemodynamics.

关 键 词：血管舒缓素 糖尿病肾病 蛋白尿 

分 类 号：R587.2[医药卫生—内分泌]